11,477 Shares in AbbVie Inc. $ABBV Purchased by Corsicana & Co.

Corsicana & Co. acquired a new stake in shares of AbbVie Inc. (NYSE:ABBV) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor acquired 11,477 shares of the company’s stock, valued at approximately $2,657,000. AbbVie comprises 1.5% of Corsicana & Co.’s portfolio, making the stock its 20th largest holding.

A number of other hedge funds also recently added to or reduced their stakes in ABBV. Lionshead Wealth Management LLC increased its holdings in shares of AbbVie by 46.0% in the third quarter. Lionshead Wealth Management LLC now owns 2,398 shares of the company’s stock valued at $555,000 after purchasing an additional 756 shares during the period. Clarity Financial LLC grew its position in AbbVie by 1.7% in the 3rd quarter. Clarity Financial LLC now owns 205,855 shares of the company’s stock valued at $47,664,000 after buying an additional 3,372 shares during the last quarter. Falcon Wealth Planning increased its stake in AbbVie by 5.4% in the 3rd quarter. Falcon Wealth Planning now owns 2,792 shares of the company’s stock valued at $646,000 after buying an additional 143 shares during the period. Focused Wealth Management Inc raised its position in AbbVie by 6.3% during the 3rd quarter. Focused Wealth Management Inc now owns 8,427 shares of the company’s stock worth $1,951,000 after buying an additional 501 shares during the last quarter. Finally, Cyndeo Wealth Partners LLC lifted its stake in shares of AbbVie by 0.5% in the 3rd quarter. Cyndeo Wealth Partners LLC now owns 131,940 shares of the company’s stock worth $30,549,000 after acquiring an additional 706 shares during the period. 70.23% of the stock is owned by institutional investors and hedge funds.

AbbVie Stock Up 2.1%

ABBV opened at $227.44 on Monday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The company has a market cap of $401.98 billion, a price-to-earnings ratio of 172.30, a PEG ratio of 1.29 and a beta of 0.36. AbbVie Inc. has a one year low of $164.39 and a one year high of $244.81. The business’s fifty day moving average is $226.63 and its two-hundred day moving average is $211.31.

AbbVie (NYSE:ABBV) last released its quarterly earnings results on Friday, October 31st. The company reported $1.86 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.77 by $0.09. AbbVie had a return on equity of 3,216.47% and a net margin of 4.00%.The business had revenue of $15.78 billion during the quarter, compared to the consensus estimate of $15.58 billion. During the same quarter in the previous year, the company posted $3.00 EPS. The business’s revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts anticipate that AbbVie Inc. will post 12.31 EPS for the current fiscal year.

AbbVie Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, February 17th. Shareholders of record on Friday, January 16th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, January 16th. This is an increase from AbbVie’s previous quarterly dividend of $1.64. This represents a $6.92 dividend on an annualized basis and a yield of 3.0%. AbbVie’s dividend payout ratio (DPR) is presently 496.97%.

Analysts Set New Price Targets

A number of brokerages have recently issued reports on ABBV. Evercore ISI boosted their price target on shares of AbbVie from $207.00 to $222.00 and gave the stock an “outperform” rating in a research note on Monday, September 22nd. Citigroup dropped their target price on AbbVie from $240.00 to $235.00 and set a “neutral” rating on the stock in a research report on Monday, November 3rd. Raymond James Financial set a $256.00 price target on AbbVie in a report on Monday, November 3rd. Guggenheim upped their price objective on AbbVie from $227.00 to $242.00 and gave the stock a “buy” rating in a report on Monday, October 20th. Finally, UBS Group increased their price objective on AbbVie from $195.00 to $220.00 and gave the stock a “neutral” rating in a research report on Friday, November 7th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have assigned a Buy rating and eight have given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $245.84.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.